Evidence map›Paper›PMID 37116146›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2023

Optimal Combination of Pitch, Modulation Factor and Dosimetric Considerations in Treatment Planning for Total Body Irradiation Using Helical Tomotherapy.

Venkatesan Kaliyaperumal, Tejinder Kataria, Singaravelu Tamilselvan, Deepak Gupta, Susan K Abraham, Kushal Narang, Susovan Banerjee, Kamaraj Dayanithi, Selvaraj Rajesh, Shyam S Bisht and 1 more

Open access · goldAbstract read
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.5field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. VMAT-based total body irradiation on a conventional LINAC: workflow, procedure and preliminary results.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Venkatesan KaliyaperumalDivision of Radiation Oncology, Medanta Cancer Institute, Medanta The Medicity, Gurgaon, Haryana, India.ORCID 0000-0002-9899-0967
Tejinder KatariaDivision of Radiation Oncology, Medanta Cancer Institute, Medanta The Medicity, Gurgaon, Haryana, India.
Singaravelu TamilselvanDivision of Radiation Oncology, Medanta Cancer Institute, Medanta The Medicity, Gurgaon, Haryana, India.
Deepak GuptaDivision of Radiation Oncology, Medanta Cancer Institute, Medanta The Medicity, Gurgaon, Haryana, India.
Susan K AbrahamDivision of Radiation Oncology, Medanta Cancer Institute, Medanta The Medicity, Gurgaon, Haryana, India.
Kushal NarangDivision of Radiation Oncology, Medanta Cancer Institute, Medanta The Medicity, Gurgaon, Haryana, India.
Susovan BanerjeeDivision of Radiation Oncology, Medanta Cancer Institute, Medanta The Medicity, Gurgaon, Haryana, India.
Kamaraj DayanithiDivision of Radiation Oncology, Medanta Cancer Institute, Medanta The Medicity, Gurgaon, Haryana, India.
Selvaraj RajeshDivision of Radiation Oncology, Medanta Cancer Institute, Medanta The Medicity, Gurgaon, Haryana, India.
Shyam S BishtDivision of Radiation Oncology, Medanta Cancer Institute, Medanta The Medicity, Gurgaon, Haryana, India.
Sorun ShishakDivision of Radiation Oncology, Medanta Cancer Institute, Medanta The Medicity, Gurgaon, Haryana, India.
Cancer Institute (WIA) · INMedanta The Medicity · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe aim of this study is to makethe standard total body irradiation (TBI) protocol for Helical tomotherapy© (HT) and to analyze the optimal pitch and modulation factor (MF) with respect to dose homogeneity index (HI), target dose coverage, target overdose, beam on time (BOT) and mean lung dose. MATERIALS AND

methodsTen patients who underwent high-dose TBI were taken for this study. For each patient, 35 dose plans were created by different combination of pitch and MF. The optimal pitch and MF were deduced using scatter plot and regression methodology based on target coverage, HI, target volume receiving 103%(V103%), 105%(V105%) and 107% (V107%) of the prescription dose and BOT. Using these optimal pitch and MF, the final dose plan was made and the planning aim and achieved dose was compared using two tailed student's t-test. Radiochromic films and ionization chambers were used to measure the delivered dose using anthropomorphic phantom on various points for the head and pelvis regions to verify the skin flash margin and its effect on skin dose.

resultsThe optimal pitch and MF value were 0.287 and 2.4 respectively. Based on optimal pitch and MF, the mean BOT was 1692 seconds with optimal inhomogeneity (7.4%). For target, D95 and D98 were 97.09% (range:94.7-99.6%, p=0.002) and 93.9% (range:91.5-94.4%,p=0.007) respectively, and mean D2 was within 107% with SD of ±1.22% (p=0.04). The mean of PTV receiving V103, V105 and V107 was 24.48% (range=7.7-36.6%, p=0.03), 5.76% (range=1.4-12.1%, SD=±3.3%), 1.93% (range=0.1-4.6%, p=0.008) respectively. Our measurements show that the flash margin did not increase the skin dose.

conclusionIn our study, the optimal combination of pitch value of 0.287 and MF value of 2.4 provided acceptable plans for all patients planned for TBI in HT. The flash margin can provide adequate coverage during patient position uncertainty without increasing the skin dose.

Indexed as

Radiotherapy, Intensity-ModulatedHumansRadiometryRadiotherapy DosageRadiotherapy Planning, Computer-AssistedWhole-Body IrradiationHelical tomotherapyModulation factorPitchSkin Dosetotal body irradiation

Identifiers

PMID37116146
PMCPMC10352750
OpenAlexW4367307795

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.